
Schrodinger, Inc.: shareholders and insiders
Price
$27.36
November 16, 2026Market cap $2.0B
What Ploutos Investor adds for Schrodinger
Part of Ploutos Investor, €9.99 a month
- The full history: 7 fiscal years, from 2019
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors from Nov 17, 2025 to Nov 12, 2026, from their own Form 4 filings.
Bought on the market
–
nobody
Sold on the market
$4.2M
7 people
From Nov 17, 2025 to Nov 17, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan100%
- The rest0%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 17, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·no buys·sold $4.2M by 7 people
- 2025: no buys, no sales
- 2026: no buys, sold $4.2M by 7 people
- Nov 11, 2026Robert Lorne AbelEVP, Chief Scientific Officer, PlatformKind10b5-1
- Nov 11, 2026Robert Lorne AbelEVP, Chief Scientific Officer, PlatformKind10b5-1
- Nov 11, 2026Robert Lorne AbelEVP, Chief Scientific Officer, PlatformKind10b5-1
- Nov 11, 2026Paul Jonathan DavieEVP, Chief Commercial Officer, Global Head of Software Sales & MarketingKind
- Nov 9, 2026Yvonne TranEVP, CLO & CPOKind10b5-1
- Nov 9, 2026Yvonne TranEVP, CLO & CPOKind10b5-1
- Nov 9, 2026Yvonne TranEVP, CLO & CPOKind10b5-1
- Nov 9, 2026Yvonne TranEVP, CLO & CPOKind10b5-1
- Nov 9, 2026Yvonne TranEVP, CLO & CPOKind10b5-1
- Sep 17, 2026Karen AkinsanyaPresident, Head of Therapeutics R&D and Chief Strategy Officer, PartnershipsKind10b5-1
- Sep 17, 2026Karen AkinsanyaPresident, Head of Therapeutics R&D and Chief Strategy Officer, PartnershipsKind10b5-1
- Sep 17, 2026Karen AkinsanyaPresident, Head of Therapeutics R&D and Chief Strategy Officer, PartnershipsKind10b5-1
- Jul 16, 2026Rachit JainEVP & CFOKind10b5-1
- Jun 26, 2026Richard FriesnerDirectorKind
- Jun 26, 2026Richard FriesnerDirectorKind
- Jun 22, 2026Arun OberoiDirectorKind
- Jun 22, 2026Jeffrey ChodakewitzDirectorKind
- Jun 22, 2026Richard FriesnerDirectorKind
- Jun 22, 2026Gary L GinsbergDirectorKind
- Jun 22, 2026Rosana Kapeller-LibermannDirectorKind
- Jun 22, 2026Michael LyntonDirectorKind
- Jun 22, 2026Gary SenderDirectorKind
- Jun 22, 2026Nancy ThornberryDirectorKind
- Jun 22, 2026Kralingen Bridget A vanDirectorKind
- Apr 17, 2026Ramy FaridPresident & CEOKind10b5-1
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 11, 2026 | Robert Lorne AbelEVP, Chief Scientific Officer, Platform | 10b5-1 | 21.9K | $17.00 | $372.8K | Form 4 |
| Nov 11, 2026 | Robert Lorne AbelEVP, Chief Scientific Officer, Platform | 10b5-1 | 21.9K | $34.00 | $745.5K | Form 4 |
| Nov 11, 2026 | Robert Lorne AbelEVP, Chief Scientific Officer, Platform | 10b5-1 | 1,678 | $34.00 | $57.1K | Form 4 |
| Nov 11, 2026 | Paul Jonathan DavieEVP, Chief Commercial Officer, Global Head of Software Sales & Marketing | 18.4K | – | – | Form 4 | |
| Nov 9, 2026 | Yvonne TranEVP, CLO & CPO | 10b5-1 | 32.0K | $17.00 | $544.0K | Form 4 |
| Nov 9, 2026 | Yvonne TranEVP, CLO & CPO | 10b5-1 | 400 | $29.97 | $12.0K | Form 4 |
| Nov 9, 2026 | Yvonne TranEVP, CLO & CPO | 10b5-1 | 2,100 | $31.45 | $66.1K | Form 4 |
| Nov 9, 2026 | Yvonne TranEVP, CLO & CPO | 10b5-1 | 7,901 | $32.64 | $257.9K | Form 4 |
| Nov 9, 2026 | Yvonne TranEVP, CLO & CPO | 10b5-1 | 21.6K | $33.11 | $715.2K | Form 4 |
| Sep 17, 2026 | Karen AkinsanyaPresident, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships | 10b5-1 | 31.6K | $4.34 | $137.1K | Form 4 |
| Sep 17, 2026 | Karen AkinsanyaPresident, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships | 10b5-1 | 10.0K | $28.00 | $280.0K | Form 4 |
| Sep 17, 2026 | Karen AkinsanyaPresident, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships | 10b5-1 | 21.6K | $30.00 | $648.0K | Form 4 |
| Jul 16, 2026 | Rachit JainEVP & CFO | 10b5-1 | 875 | $15.60 | $13.6K | Form 4 |
| Jun 26, 2026 | Richard FriesnerDirector | 679.4K | – | – | Form 4 | |
| Jun 26, 2026 | Richard FriesnerDirector | 679.4K | – | – | Form 4 | |
| Jun 22, 2026 | Arun OberoiDirector | 8,141 | – | – | Form 4 | |
| Jun 22, 2026 | Jeffrey ChodakewitzDirector | 8,141 | – | – | Form 4 | |
| Jun 22, 2026 | Richard FriesnerDirector | 8,141 | – | – | Form 4 | |
| Jun 22, 2026 | Gary L GinsbergDirector | 8,141 | – | – | Form 4 | |
| Jun 22, 2026 | Rosana Kapeller-LibermannDirector | 8,141 | – | – | Form 4 | |
| Jun 22, 2026 | Michael LyntonDirector | 8,141 | – | – | Form 4 | |
| Jun 22, 2026 | Gary SenderDirector | 8,141 | – | – | Form 4 | |
| Jun 22, 2026 | Nancy ThornberryDirector | 8,141 | – | – | Form 4 | |
| Jun 22, 2026 | Kralingen Bridget A vanDirector | 8,141 | – | – | Form 4 | |
| Apr 17, 2026 | Ramy FaridPresident & CEO | 10b5-1 | 43.0K | $12.21 | $525.0K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 23, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by SDGR's officers and directors from 2020 up to November 16, 2025, 6 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 1 more, back to 2020
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- BlackRock, Inc.Share of class12.7%
- Rubric Capital Management LPwith 1 more personShare of class9.28%
- Vanguard Portfolio ManagementShare of class6.04%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| BlackRock, Inc. | 12.7% | 8.16M | Jul 18, 2025 | 13G/A | |
| Rubric Capital Management LPwith 1 more person | 9.28% | 6.00M | May 15, 20263 filings since Feb 13, 2025 | 13G/A | |
| Vanguard Portfolio Management | 6.04% | 3.91M | Apr 29, 2026 | 13G |
Fell to 5% or less (2)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Citadel Advisors (Griffin)In the quarter+354%
- AQR CapitalIn the quarter+340%
- Millennium Mgmt (Englander)In the quarter
- D.E. ShawIn the quarter
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Citadel Advisors (Griffin) | 895.8K | +354% | $15M | 0.01% |
| AQR Capital | 1.96M | +340% | $32M | 0.01% |
| Millennium Mgmt (Englander) | – | – | 0.00% | |
| D.E. Shaw | – | – | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 14.2% of its shares outstanding were held short, +2.7% since the report before.
- Shares held short
- 10.40M
- 14.2%
- Since the report before10.13M on Sep 30, 2026
- +2.7%
- 3.4
- 3.10M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 39%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 6.94M
- Nov 15, 2023: Shares held short 6.60M
- Nov 30, 2023: Shares held short 6.76M
- Dec 15, 2023: Shares held short 6.76M
- Dec 29, 2023: Shares held short 6.47M
- Jan 12, 2024: Shares held short 6.17M
- Jan 31, 2024: Shares held short 5.48M
- Feb 15, 2024: Shares held short 5.47M
- Feb 29, 2024: Shares held short 5.41M
- Mar 15, 2024: Shares held short 5.92M
- Mar 28, 2024: Shares held short 6.24M
- Apr 15, 2024: Shares held short 6.42M
- Apr 30, 2024: Shares held short 7.01M
- May 15, 2024: Shares held short 7.89M
- May 31, 2024: Shares held short 7.75M
- Jun 14, 2024: Shares held short 8.13M
- Jun 28, 2024: Shares held short 8.27M
- Jul 15, 2024: Shares held short 8.20M
- Jul 31, 2024: Shares held short 7.99M
- Aug 15, 2024: Shares held short 8.41M
- Aug 30, 2024: Shares held short 8.73M
- Sep 13, 2024: Shares held short 8.76M
- Sep 30, 2024: Shares held short 8.79M
- Oct 15, 2024: Shares held short 8.84M
- Oct 31, 2024: Shares held short 8.90M
- Nov 15, 2024: Shares held short 9.33M
- Nov 29, 2024: Shares held short 9.16M
- Dec 13, 2024: Shares held short 9.00M
- Dec 31, 2024: Shares held short 9.56M
- Jan 15, 2025: Shares held short 9.82M
- Jan 31, 2025: Shares held short 10.00M
- Feb 14, 2025: Shares held short 9.94M
- Feb 28, 2025: Shares held short 9.25M
- Mar 14, 2025: Shares held short 8.89M
- Mar 31, 2025: Shares held short 9.34M
- Apr 15, 2025: Shares held short 10.61M
- Apr 30, 2025: Shares held short 9.95M
- May 15, 2025: Shares held short 10.22M
- May 30, 2025: Shares held short 10.69M
- Jun 13, 2025: Shares held short 10.48M
- Jun 30, 2025: Shares held short 11.16M
- Jul 15, 2025: Shares held short 11.11M
- Jul 31, 2025: Shares held short 9.34M
- Aug 15, 2025: Shares held short 9.64M
- Aug 29, 2025: Shares held short 9.35M
- Sep 15, 2025: Shares held short 10.52M
- Sep 30, 2025: Shares held short 9.71M
- Oct 15, 2025: Shares held short 9.64M
- Oct 31, 2025: Shares held short 9.82M
- Nov 14, 2025: Shares held short 10.01M
- Nov 28, 2025: Shares held short 10.33M
- Dec 15, 2025: Shares held short 9.37M
- Dec 31, 2025: Shares held short 9.53M
- Jan 15, 2026: Shares held short 10.58M
- Jan 30, 2026: Shares held short 10.90M
- Feb 13, 2026: Shares held short 10.71M
- Feb 27, 2026: Shares held short 11.07M
- Mar 13, 2026: Shares held short 11.32M
- Mar 31, 2026: Shares held short 11.11M
- Apr 15, 2026: Shares held short 10.91M
- Apr 30, 2026: Shares held short 10.38M
- May 15, 2026: Shares held short 10.27M
- May 29, 2026: Shares held short 10.42M
- Jun 15, 2026: Shares held short 10.02M
- Jun 30, 2026: Shares held short 10.51M
- Jul 15, 2026: Shares held short 10.58M
- Jul 31, 2026: Shares held short 11.01M
- Aug 14, 2026: Shares held short 11.43M
- Aug 31, 2026: Shares held short 11.09M
- Sep 15, 2026: Shares held short 11.17M
- Sep 30, 2026: Shares held short 10.13M
- Oct 15, 2026: Shares held short 10.40M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading50.2% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 50.2% of the shares in the reported trades were short sales, against 45.7% in the 14 before.
- Last 14 sessionsOct 28, 2026 – Nov 16, 2026
- 50.2%
- The 14 beforeOct 8, 2026 – Oct 27, 2026
- 45.7%
- Change
- +4.5 pts
- Short sales a dayon average, of 751.4K shares
- 377.5K
- More than atof 3,668 US-listed companies, same days
- 50%
- Median of alleight in ten from 34.7% to 63.8%
- 50.3%
- Short sales
- Oct 8, 2026: Short sales 43.6%
- Oct 9, 2026: Short sales 41%
- Oct 12, 2026: Short sales 34.2%
- Oct 13, 2026: Short sales 48%
- Oct 14, 2026: Short sales 43%
- Oct 15, 2026: Short sales 41.3%
- Oct 16, 2026: Short sales 54.8%
- Oct 19, 2026: Short sales 49.8%
- Oct 20, 2026: Short sales 48.8%
- Oct 21, 2026: Short sales 51.5%
- Oct 22, 2026: Short sales 32.8%
- Oct 23, 2026: Short sales 46.1%
- Oct 26, 2026: Short sales 50.3%
- Oct 27, 2026: Short sales 58.8%
- Oct 28, 2026: Short sales 51.8%
- Oct 29, 2026: Short sales 57.6%
- Oct 30, 2026: Short sales 44.6%
- Nov 2, 2026: Short sales 52.4%
- Nov 3, 2026: Short sales 51.3%
- Nov 4, 2026: Short sales 57.7%
- Nov 5, 2026: Short sales 39.2%
- Nov 6, 2026: Short sales 48.1%
- Nov 9, 2026: Short sales 41%
- Nov 10, 2026: Short sales 54.1%
- Nov 11, 2026: Short sales 59.8%
- Nov 12, 2026: Short sales 58.9%
- Nov 13, 2026: Short sales 48.5%
- Nov 16, 2026: Short sales 47.6%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Richard FriesnerDirectorDirectly1.41M
- Ramy FaridPresident & CEODirectly330.8K
- Robert Lorne AbelSee RemarksDirectly110.1K
- Kenneth Patrick LortonEVP, CTO & COO, SoftwareDirectly89.2K
- Karen AkinsanyaSee RemarksDirectly70.0K
- Yvonne TranEVP, CLO & CPODirectly52.7K
- Rachit JainEVP & CFODirectly50.9K
- Jenny HermanCAODirectly34.8K
- Geoffrey Craig PorgesEVP & CFODirectly27.5K
- Arun OberoiDirectorDirectly25.4K
- Jeffrey ChodakewitzDirectorDirectly25.4K
- Gary L GinsbergDirectorDirectly25.4K
- Rosana Kapeller-LibermannDirectorDirectly25.4K
- Michael LyntonDirectorDirectly25.4K
- Gary SenderDirectorDirectly25.4K
- Nancy ThornberryDirectorDirectly25.4K
- Margaret DuganChief Medical OfficerDirectly24.6K
- Kralingen Bridget A vanDirectorDirectly19.6K
- Paul Jonathan DavieEVP, Chief Commercial Officer, Global Head of Software Sales & MarketingDirectly18.4K
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Richard FriesnerDirector | 1.41M | – | Jun 26, 2026 | Form 4 |
| Ramy FaridPresident & CEO | 330.8K | – | Apr 17, 2026 | Form 4 |
| Robert Lorne AbelSee Remarks | 110.1K | – | Nov 11, 2026 | Form 4 |
| Kenneth Patrick LortonEVP, CTO & COO, Software | 89.2K | – | Mar 5, 2026 | Form 4 |
| Karen AkinsanyaSee Remarks | 70.0K | – | Sep 17, 2026 | Form 4 |
| Yvonne TranEVP, CLO & CPO | 52.7K | – | Nov 9, 2026 | Form 4 |
| Rachit JainEVP & CFO | 50.9K | – | Jul 16, 2026 | Form 4 |
| Jenny HermanCAO | 34.8K | – | Mar 6, 2026 | Form 4 |
| Geoffrey Craig PorgesEVP & CFO | 27.5K | – | Mar 3, 2025 | Form 4 |
| Arun OberoiDirector | 25.4K | – | Jun 22, 2026 | Form 4 |
| Jeffrey ChodakewitzDirector | 25.4K | – | Jun 22, 2026 | Form 4 |
| Gary L GinsbergDirector | 25.4K | – | Jun 22, 2026 | Form 4 |
| Rosana Kapeller-LibermannDirector | 25.4K | – | Jun 22, 2026 | Form 4 |
| Michael LyntonDirector | 25.4K | – | Jun 22, 2026 | Form 4 |
| Gary SenderDirector | 25.4K | – | Jun 22, 2026 | Form 4 |
| Nancy ThornberryDirector | 25.4K | – | Jun 22, 2026 | Form 4 |
| Margaret DuganChief Medical Officer | 24.6K | – | Oct 16, 2025 | Form 4 |
| Kralingen Bridget A vanDirector | 19.6K | – | Jun 22, 2026 | Form 4 |
| Paul Jonathan DavieEVP, Chief Commercial Officer, Global Head of Software Sales & Marketing | 18.4K | – | Nov 11, 2026 | Form 4 |
A lower bound: it counts only the 19 officers and directors with a market trade since Nov 18, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 269 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- ARKGARK Genomic Revolution ETFWeight in the fund1.99%
- IWOiShares Russell 2000 Growth ETFWeight in the fund0.06%
- IJRiShares Core S&P Small-Cap ETFWeight in the fund0.05%
- SPSMState Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETFWeight in the fund0.05%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.04%
- IWMiShares Russell 2000 ETFWeight in the fund0.03%
- VBKVanguard Small-Cap Growth Index FundWeight in the fund0.03%
- SCHASchwab U.S. Small-Cap ETFWeight in the fund0.02%
- VHTVanguard Health Care Index FundWeight in the fund0.02%
- VBVanguard Small-Cap Index FundWeight in the fund0.01%
18 of the 269 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 226
- Q4 2025: Managers 223
- Q1 2026: Managers 230
- Q2 2026: Managers 231
Institutional investors by quarter
The fund managers holding SDGR, quarter by quarter, from Q1 2020 to Q2 2025, 22 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 231 managers held 64.71M shares, worth $1.1B. During the quarter 46 opened a position, 45 closed one, 80 added and 61 trimmed.
The largest holders, Q2 2026
- BlackRockIn the quarter+8.7%
- Gates Foundation TrustIn the quarter
- Rubric Capital ManagementIn the quarter+6.7%
- Vanguard Portfolio ManagementIn the quarter-1.9%
- Amova Asset Management AmericasIn the quarter-15%
- Sumitomo Mitsui Trust GroupIn the quarter-15%
- Vanguard Capital ManagementIn the quarter+3.3%
- State StreetIn the quarter+4.9%
- UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICASIn the quarter-16%
- ARK Investment ManagementIn the quarter+4.2%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| BlackRock | 10.52M | +8.7% | $171M |
| Gates Foundation Trust | 6.98M | $113M | |
| Rubric Capital Management | 6.40M | +6.7% | $104M |
| Vanguard Portfolio Management | 3.79M | -1.9% | $62M |
| Amova Asset Management Americas | 2.71M | -15% | $44M |
| Sumitomo Mitsui Trust Group | 2.71M | -15% | $44M |
| Vanguard Capital Management | 2.69M | +3.3% | $44M |
| State Street | 2.30M | +4.9% | $37M |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS | 2.22M | -16% | $36M |
| ARK Investment Management | 2.15M | +4.2% | $35M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Schrodinger's filings show?
Who buys and sells is one part of Schrodinger's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have SDGR's insiders bought or sold?
From Jun 23, 2026 to Nov 12, 2026 Schrodinger's insiders bought 0 and sold $2.8M of shares on the market. 100% of the sales were under set 10b5-1 plans.
Which well-known managers hold SDGR?
4 of the managers we track held the shares on Jun 30, 2026. The largest position was AQR Capital's, worth $32M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.